Stanford Advisors


All Publications


  • Computational design of HLA class I superbinders for broad T cell immunogenicity PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Peer, E., Cohen-Lavi, L., Sette, A., Sidney, J., Hertz, T. 2026; 123 (18): e2518820123

    Abstract

    Human leukocyte antigen (HLA) class I molecules are highly polymorphic, restricting peptide binding to narrow sequence subsets. Designing peptides that bind multiple HLA supertypes-termed superbinders-offers a promising strategy for broad-spectrum T cell vaccines and immunotherapies. Here, we present superHLA, a computational framework that combines Markov Chain Monte Carlo optimization with state-of-the-art major histocompatibility complex binding predictors to design synthetic 9-mer peptides with broad HLA-binding profiles. Using superHLA, we generated over 190,000 candidate superbinders predicted to bind 8 to 12 HLA class I alleles across distinct supertypes. A multitier filtering pipeline-incorporating sequence clustering, synthesis feasibility, cross-predictor validation, and self-peptidome exclusion-yielded a final panel of 100 peptides for experimental testing. Of these, 21 bound 4 to 9 supertypes in vitro. Superbinders displayed distinct anchor residue preferences and showed minimal similarity to human peptides. These results suggest that HLA superbinders are more abundant than previously recognized and can be rationally designed at scale. This approach supports development of pan-HLA immunogens with broad population coverage and may inform applications in vaccine research, neoantigen discovery, and immunotherapy.

    View details for DOI 10.1073/pnas.2518820123

    View details for Web of Science ID 001780461100024

    View details for PubMedID 42048449

    View details for PubMedCentralID PMC13142983

  • Mapping antibody footprints using binding profiles CELL REPORTS METHODS Azulay, A., Cohen-Lavi, L., Friedman, L. M., Mcgargill, M. A., Hertz, T. 2023; 3 (8): 100566

    Abstract

    The increasing use of monoclonal antibodies (mAbs) in biology and medicine necessitates efficient methods for characterizing their binding epitopes. Here, we developed a high-throughput antibody footprinting method based on binding profiles. We used an antigen microarray to profile 23 human anti-influenza hemagglutinin (HA) mAbs using HA proteins of 43 human influenza strains isolated between 1918 and 2018. We showed that the mAb's binding profile can be used to characterize its influenza subtype specificity, binding region, and binding site. We present mAb-Patch-an epitope prediction method that is based on a mAb's binding profile and the 3D structure of its antigen. mAb-Patch was evaluated using four mAbs with known solved mAb-HA structures. mAb-Patch identifies over 67% of the true epitope when considering only 50-60 positions along the antigen. Our work provides proof of concept for utilizing antibody binding profiles to screen large panels of mAbs and to down-select antibodies for further functional studies.

    View details for DOI 10.1016/j.crmeth.2023.100566

    View details for Web of Science ID 001090566900001

    View details for PubMedID 37671022

    View details for PubMedCentralID PMC10475849

  • Benchmarking solutions to the T-cell receptor epitope prediction problem: IMMREP22 workshop report ImmunoInformatics Meysman, P., Barton, J., Bravi, B., Cohen-Lavi, L., Karnaukhov, V., Lilleskov, E., Montemurro, A., Nielsen, M., Mora, T., et al 2023; 9
  • Defining the risk of SARS-CoV-2 variants on immune protection NATURE DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., Bloom, J. D., Bloyet, L., Bonenfant, G., Boon, A. C. M., Boritz, E. A., Bratt, D. L., Bricker, T. L., Brown, L., Buchser, W. J., Carreno, J., Cohen-Lavi, L., Darling, T. L., Davis-Gardner, M. E., Dearlove, B. L., Di, H., Dittmann, M., Doria-Rose, N. A., Douek, D. C., Drosten, C., Edara, V., Ellebedy, A., Fabrizio, T. P., Ferrari, G., Fischer, W. M., Florence, W. C., Fouchier, R. A. M., Franks, J., Garcia-Sastre, A., Godzik, A., Gonzalez-Reiche, A., Gordon, A., Haagmans, B. L., Halfmann, P. J., Ho, D. D., Holbrook, M. R., Huang, Y., James, S. L., Jaroszewski, L., Jeevan, T., Johnson, R. M., Jones, T. C., Joshi, A., Kawaoka, Y., Kercher, L., Koopmans, M. P. G., Korber, B., Koren, E., Koup, R. A., LeGresley, E. B., Lemieux, J. E., Liebeskind, M. J., Liu, Z., Livingston, B., Logue, J. P., Luo, Y., McDermott, A. B., McElrath, M. J., Meliopoulos, V. A., Menachery, V. D., Montefiori, D. C., Muehlemann, B., Munster, V. J., Munt, J. E., Nair, M. S., Netzl, A., Niewiadomska, A. M., O'Dell, S., Pekosz, A., Perlman, S., Pontelli, M. C., Rockx, B., Rolland, M., Rothlauf, P. W., Sacharen, S., Scheuermann, R. H., Schmidt, S. D., Schotsaert, M., Schultz-Cherry, S., Seder, R. A., Sedova, M., Sette, A., Shabman, R. S., Shen, X., Shi, P., Shukla, M., Simon, V., Stumpf, S., Sullivan, N. J., Thackray, L. B., Theiler, J., Thomas, P. G., Trifkovic, S., Tureli, S., Turner, S. A., Vakaki, M. A., van Bakel, H., VanBlargan, L. A., Vincent, L. R., Wallace, Z. S., Wang, L., Wang, M., Wang, P., Wang, W., Weaver, S. C., Webby, R. J., Weiss, C. D., Wentworth, D. E., Weston, S. M., Whelan, S. P. J., Whitener, B. M., Wilks, S. H., Xie, X., Ying, B., Yoon, H., Zhou, B., Hertz, T., Smith, D. J., Diamond, M. S., Post, D. J., Suthar, M. S. 2022; 605 (7911): 640-652

    Abstract

    The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.

    View details for DOI 10.1038/s41586-022-04690-5

    View details for Web of Science ID 000797787500001

    View details for PubMedID 35361968

    View details for PubMedCentralID PMC9345323

  • TCR meta-clonotypes for biomarker discovery with <i>tcrdist3</i> enabled identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs ELIFE Mayer-Blackwell, K., Schattgen, S., Cohen-Lavi, L., Crawford, J. C., Souquette, A., Gaevert, J. A., Hertz, T., Thomas, P. G., Bradley, P. G., Fiore-Gartland, A. 2021; 10

    Abstract

    T-cell receptors (TCRs) encode clinically valuable information that reflects prior antigen exposure and potential future response. However, despite advances in deep repertoire sequencing, enormous TCR diversity complicates the use of TCR clonotypes as clinical biomarkers. We propose a new framework that leverages experimentally inferred antigen-associated TCRs to form meta-clonotypes - groups of biochemically similar TCRs - that can be used to robustly quantify functionally similar TCRs in bulk repertoires across individuals. We apply the framework to TCR data from COVID-19 patients, generating 1831 public TCR meta-clonotypes from the SARS-CoV-2 antigen-associated TCRs that have strong evidence of restriction to patients with a specific human leukocyte antigen (HLA) genotype. Applied to independent cohorts, meta-clonotypes targeting these specific epitopes were more frequently detected in bulk repertoires compared to exact amino acid matches, and 59.7% (1093/1831) were more abundant among COVID-19 patients that expressed the putative restricting HLA allele (false discovery rate [FDR]<0.01), demonstrating the potential utility of meta-clonotypes as antigen-specific features for biomarker development. To enable further applications, we developed an open-source software package, tcrdist3, that implements this framework and facilitates flexible workflows for distance-based TCR repertoire analysis.

    View details for DOI 10.7554/eLife.68605.sa2

    View details for Web of Science ID 000730626100001

    View details for PubMedID 34845983

    View details for PubMedCentralID PMC8631793

  • Governing convergence of Max-sum on DCOPs through damping and splitting ARTIFICIAL INTELLIGENCE Cohen, L., Galiki, R., Zivan, R. 2020; 279
  • Validity of machine learning in biology and medicine increased through collaborations across fields of expertise NATURE MACHINE INTELLIGENCE Littmann, M., Selig, K., Cohen-Lavi, L., Frank, Y., Hoenigschmid, P., Kataka, E., Moesch, A., Qian, K., Ron, A., Schmid, S., Sorbie, A., Szlak, L., Dagan-Wiener, A., Ben-Tal, N., Niv, M. Y., Razansky, D., Schuller, B. W., Ankerst, D., Hertz, T., Rost, B. 2020; 2 (1): 18-24
  • A Modular Cytokine Analysis Method Reveals Novel Associations With Clinical Phenotypes and Identifies Sets of Co-signaling Cytokines Across Influenza Natural Infection Cohorts and Healthy Controls FRONTIERS IN IMMUNOLOGY Cohen, L., Fiore-Gartland, A., Randoplh, A. G., Panoskaltsis-Mortari, A., Wong, S., Ralston, J., Wood, T., Seeds, R., Huang, Q., Webby, R. J., Thomas, P. G., Hertz, T. 2019; 10: 1338

    Abstract

    Cytokines and chemokines are key signaling molecules of the immune system. Recent technological advances enable measurement of multiplexed cytokine profiles in biological samples. These profiles can then be used to identify potential biomarkers of a variety of clinical phenotypes. However, testing for such associations for each cytokine separately ignores the highly context-dependent covariation in cytokine secretion and decreases statistical power to detect associations due to multiple hypothesis testing. Here we present CytoMod-a novel data-driven approach for analysis of cytokine profiles that uses unsupervised clustering and regression to identify putative functional modules of co-signaling cytokines. Each module represents a biosignature of co-signaling cytokines. We applied this approach to three independent clinical cohorts of subjects naturally infected with influenza in which cytokine profiles and clinical phenotypes were collected. We found that in two out of three cohorts, cytokine modules were significantly associated with clinical phenotypes, and in many cases these associations were stronger than the associations of the individual cytokines within them. By comparing cytokine modules across datasets, we identified cytokine "cores"-specific subsets of co-expressed cytokines that clustered together across the three cohorts. Cytokine cores were also associated with clinical phenotypes. Interestingly, most of these cores were also co-expressed in a cohort of healthy controls, suggesting that in part, patterns of cytokine co-signaling may be generalizable. CytoMod can be readily applied to any cytokine profile dataset regardless of measurement technology, increases the statistical power to detect associations with clinical phenotypes and may help shed light on the complex co-signaling networks of cytokines in both health and infection.

    View details for DOI 10.3389/fimmu.2019.01338

    View details for Web of Science ID 000471920400001

    View details for PubMedID 31275311

    View details for PubMedCentralID PMC6594355

  • BenchRep-T: A Systematic Evaluation of T-Cell Repertoire-Based Disease Diagnostics. bioRxiv : the preprint server for biology Im, C., Cohen-Lavi, L., Buendia, A., Kundaje, A., Boyd, S. D. 2026

    Abstract

    Adaptive immune receptor repertoire sequencing data has emerged as a promising potential modality for disease diagnosis, relying on computational methods to analyze T-cell receptor (TCR) sequences from an individual's blood sample. Published methods rely on different cohorts, data preprocessing pipelines, and evaluation metrics, making direct comparison across methods challenging. We present BenchRep-T, a unified benchmark that standardizes multiple publicly available TCR repertoire datasets and evaluates nine computational approaches, spanning statistical enrichment of shared sequences, feature-engineered ensembles, deep learning, and sequence clustering. BenchRep-T evaluates methods on four tasks: disease classification across conditions, performance scaling under restricted sequence-sampling depth, recovery of known antigen-specific driver sequences, and evaluation of sensitivity to demographic confounding. Under controlled evaluation, simple baselines prove competitive, with tree-based models trained on V- and J-gene usage and short sequence motifs approaching the classification performance of more complex methods. Our findings underscore the complexity of modeling TCR repertoire data, and show that no single method dominates across all tasks. BenchRep-T provides a framework for rigorous and reproducible evaluation of TCR repertoire classification methods to accelerate the development of immune repertoire-based diagnostics.

    View details for DOI 10.64898/2026.06.09.727013

    View details for PubMedID 42327158

    View details for PubMedCentralID PMC13277846

  • Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2 NATURE COMMUNICATIONS Hertz, T., Levy, S., Ostrovsky, D., Oppenheimer, H., Zismanov, S., Kuzmina, A., Friedman, L. M., Trifkovic, S., Brice, D., Chun-Yang, L., Cohen-Lavi, L., Shemer-Avni, Y., Cohen-Lahav, M., Amichay, D., Keren-Naus, A., Voloshin, O., Weber, G., Najjar-Debbiny, R., Chazan, B., McGargill, M. A., Webby, R., Chowers, M., Novack, L., Novack, V., Taube, R., Nesher, L., Weinstein, O. 2023; 14 (1): 4575

    Abstract

    Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.

    View details for DOI 10.1038/s41467-023-39816-4

    View details for Web of Science ID 001039984300015

    View details for PubMedID 37516771

    View details for PubMedCentralID PMC10387073

  • US National Institutes of Health Prioritization of SARS-CoV-2 Variants EMERGING INFECTIOUS DISEASES Turner, S., Alisoltani, A., Bratt, D., Cohen-Lavi, L., Dearlove, B. L., Drosten, C., Fischer, W. M., Fouchier, R. A. M., Gonzalez-Reiche, A., Jaroszewski, L., Khalil, Z., LeGresley, E., Johnson, M., Jones, T. C., Muehlemann, B., O'Connor, D., Sedova, M., Shukla, M., Theiler, J., Wallace, Z. S., Yoon, H., Zhang, Y., van Bakel, H., Degrace, M. M., Ghedin, E., Godzik, A., Hertz, T., Korber, B., Lemieux, J., Niewiadomska, A. M., Post, D. J., Rolland, M., Scheuermann, R., Smith, D. J. 2023; 29 (5): E1-E9

    Abstract

    Since late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. The group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic properties of emerging and circulating strains to identify the most relevant variants for experimental groups within the program to phenotypically characterize. Since April 2021, the group has prioritized variants monthly. Prioritization successes include rapidly identifying most major variants of SARS-CoV-2 and providing experimental groups within the National Institutes of Health program easy access to regularly updated information on the recent evolution and epidemiology of SARS-CoV-2 that can be used to guide phenotypic investigations.

    View details for DOI 10.3201/eid2905.221646

    View details for Web of Science ID 000994459900001

    View details for PubMedID 37054986

    View details for PubMedCentralID PMC10124642

  • Obesity Is Associated with an Impaired Baseline Repertoire of Anti-Influenza Virus Antibodies MICROBIOLOGY SPECTRUM Abd Alhadi, M., Friedman, L. M., Karlsson, E. A., Cohen-Lavi, L., Burkovitz, A., Schultz-Cherry, S., Noah, T. L., Weir, S. S., Shulman, L. M., Beck, M. A., Hertz, T. 2023; 11 (3): e0001023

    Abstract

    Obesity is a risk factor for severe disease and mortality for both influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. While previous studies show that individuals with obesity generate antibody responses following influenza vaccination, infection rates within the obese group were twice as high as those in the healthy-weight group. The repertoire of antibodies raised against influenza viruses following previous vaccinations and/or natural exposures is referred to here as baseline immune history (BIH). To investigate the hypothesis that obesity impacts immune memory to infections and vaccines, we profiled the BIH of obese and healthy-weight adults vaccinated with the 2010-2011 seasonal influenza vaccine in response to conformational and linear antigens. Despite the extensive heterogeneity of the BIH profiles in both groups, there were striking differences between obese and healthy subjects, especially with regard to A/H1N1 strains and the 2009 pandemic virus (Cal09). Individuals with obesity had lower IgG and IgA magnitude and breadth for a panel of A/H1N1 whole viruses and hemagglutinin proteins from 1933 to 2009 but increased IgG magnitude and breadth for linear peptides from the Cal09 H1 and N1 proteins. Age was also associated with A/H1N1 BIH, with young individuals with obesity being more likely to have reduced A/H1N1 BIH. We found that individuals with low IgG BIH had significantly lower neutralizing antibody titers than individuals with high IgG BIH. Taken together, our findings suggest that increased susceptibility of obese participants to influenza infection may be mediated in part by obesity-associated differences in the memory B-cell repertoire, which cannot be ameliorated by current seasonal vaccination regimens. Overall, these data have vital implications for the next generation of influenza virus and SARS-CoV-2 vaccines. IMPORTANCE Obesity is associated with increased morbidity and mortality from influenza and SARS-CoV-2 infection. While vaccination is the most effective strategy for preventing influenza virus infection, our previous studies showed that influenza vaccines fail to provide optimal protection in obese individuals despite reaching canonical correlates of protection. Here, we show that obesity may impair immune history in humans and cannot be overcome by seasonal vaccination, especially in younger individuals with decreased lifetime exposure to infections and seasonal vaccines. Low baseline immune history is associated with decreased protective antibody responses. Obesity potentially handicaps overall responses to vaccination, biasing it toward responses to linear epitopes, which may reduce protective capacity. Taken together, our data suggest that young obese individuals are at an increased risk of reduced protection by vaccination, likely due to altered immune history biased toward nonprotective antibody responses. Given the worldwide obesity epidemic coupled with seasonal respiratory virus infections and the inevitable next pandemic, it is imperative that we understand and improve vaccine efficacy in this high-risk population. The design, development, and usage of vaccines for and in obese individuals may need critical evaluation, and immune history should be considered an alternate correlate of protection in future vaccine clinical trials.

    View details for DOI 10.1128/spectrum.00010-23

    View details for Web of Science ID 000976876900001

    View details for PubMedID 37098954

    View details for PubMedCentralID PMC10269616

  • Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: Observations from a randomized controlled trial in patients with Crohn's disease BRAIN BEHAVIOR & IMMUNITY-HEALTH Nemirovsky, A., Ilan, K., Lerner, L., Cohen-Lavi, L., Schwartz, D., Goren, G., Sergienko, R., Greenberg, D., Slonim-Nevo, V., Sarid, O., Friger, M., Regev, S., Odes, S., Hertz, T., Monsonego, A. 2022; 19: 100407

    Abstract

    Crohn's disease (CD) is a chronic inflammatory bowel disease associated with psychological stress that is regulated primarily by the hypothalamus-pituitary-adrenal (HPA) axis. Here, we determined whether the psychological characteristics of CD patients associate with their inflammatory state, and whether a 3-month trial of cognitive-behavioral and mindfulness-based stress reduction (COBMINDEX) impacts their inflammatory process.Circulating inflammatory markers and a wide range of psychological parameters related to stress and well-being were measured in CD patients before and after COBMINDEX. Inflammatory markers in CD patients were also compared to age- and sex-matched healthy controls (HCs).CD patients exhibited increased peripheral low-grade inflammation compared with HCs, demonstrated by interconnected inflammatory modules represented by IL-6, TNFα, IL-17, MCP-1 and IL-18. Notably, higher IL-18 levels correlated with higher score of stress and a lower score of wellbeing in CD patients. COBMINDEX was accompanied by changes in inflammatory markers that coincided with changes in cortisol: changes in serum levels of cortisol correlated positively with those of IL-10 and IFNα and negatively with those of MCP-1. Furthermore, inflammatory markers of CD patients at baseline predicted COBMINDEX efficacy, as higher levels of distinct cytokines and cortisol at baseline, correlated negatively with changes in disease activity (by Harvey-Bradshaw Index) and psychological distress (global severity index measure) following COBMINDEX.CD patients have a characteristic immunological profile that correlates with psychological stress, and disease severity. We suggest that COBMINDEX induces stress resilience in CD patients, which impacts their well-being, and their disease-associated inflammatory process.

    View details for DOI 10.1016/j.bbih.2021.100407

    View details for Web of Science ID 001066602400015

    View details for PubMedID 35024638

    View details for PubMedCentralID PMC8728050

  • Machine learning applied to multi-sensor information to reduce false alarm rate in the ICU JOURNAL OF CLINICAL MONITORING AND COMPUTING Hever, G., Cohen, L., O'Connor, M. F., Matot, I., Lerner, B., Bitan, Y. 2020; 34 (2): 339-352

    Abstract

    Studies reveal that the false alarm rate (FAR) demonstrated by intensive care unit (ICU) vital signs monitors ranges from 0.72 to 0.99. We applied machine learning (ML) to ICU multi-sensor information to imitate a medical specialist in diagnosing patient condition. We hypothesized that applying this data-driven approach to medical monitors will help reduce the FAR even when data from sensors are missing. An expert-based rules algorithm identified and tagged in our dataset seven clinical alarm scenarios. We compared a random forest (RF) ML model trained using the tagged data, where parameters (e.g., heart rate or blood pressure) were (deliberately) removed, in detecting ICU signals with the full expert-based rules (FER), our ground truth, and partial expert-based rules (PER), missing these parameters. When all alarm scenarios were examined, RF and FER were almost identical. However, in the absence of one to three parameters, RF maintained its values of the Youden index (0.94-0.97) and positive predictive value (PPV) (0.98-0.99), whereas PER lost its value (0.54-0.8 and 0.76-0.88, respectively). While the FAR for PER with missing parameters was 0.17-0.39, it was only 0.01-0.02 for RF. When scenarios were examined separately, RF showed clear superiority in almost all combinations of scenarios and numbers of missing parameters. When sensor data are missing, specialist performance worsens with the number of missing parameters, whereas the RF model attains high accuracy and low FAR due to its ability to fuse information from available sensors, compensating for missing parameters.

    View details for DOI 10.1007/s10877-019-00307-x

    View details for Web of Science ID 000520481100018

    View details for PubMedID 30955160

  • Applying Max-sum to asymmetric distributed constraint optimization problems AUTONOMOUS AGENTS AND MULTI-AGENT SYSTEMS Zivan, R., Parash, T., Cohen-Lavi, L., Naveh, Y. 2020; 34 (1)
  • Balancing Asymmetry in Max-sum Using Split Constraint Factor Graphs Cohen, L., Zivan, R. edited by Hooker, J. SPRINGER INTERNATIONAL PUBLISHING AG. 2018: 669-687
  • Balancing exploration and exploitation in incomplete Min/Max-sum inference for distributed constraint optimization AUTONOMOUS AGENTS AND MULTI-AGENT SYSTEMS Zivan, R., Parash, T., Cohen, L., Peled, H., Okamoto, S. 2017; 31 (5): 1165-1207
  • Max-sum Revisited; The Real Power of Damping Cohen, L., Zivan, R., Assoc Comp Machinery ASSOC COMPUTING MACHINERY. 2017: 1505-1507